BACKGROUND: Primary graft dysfunction (PGD) represents ischemia-reperfusion injury in the lung allograft, and elevated left ventricular end-diastolic pressure (LVEDP) may contribute to capillary leak. We tested whether pre-transplant LVEDP or pulmonary capillary wedge pressure (mPCWP) are related to PGD risk. We hypothesized that elevated LVEDP and mPCWP would increase PGD risk. METHODS: We reviewed adult double lung transplant recipients at the University of Alberta Hospital from 2004 to 2016 with pre-transplant LVEDP measurements. The primary outcome was Grade 3 PGD at 48 to 72 hours post-transplant. We used regression analysis to assess the association between LVEDP and mPCWP with Grade 3 PGD risk, as well as agreement between these measurements. RESULTS: Three hundred thirty double lung transplant recipients were included in the study, and 63 (19%) developed Grade 3 PGD at 48 or 72 hours. Mean LVEDP was 16 § 7 mm Hg in the Grade 3 PGD group and 12 § 5 mm Hg in the non-PGD group (p < 0.0001). LVEDP >15 mm Hg was associated with an adjusted odds ratio (OR) of 3.83 (95% confidence interval [CI] 1.90 to 7.73, p < 0.0001), whereas mPCWP >15 mm Hg showed similar findings (adjusted OR 4.25 [1.83 to 9.86], p = 0.0008). Correlation and agreement between LVEDP and mPCWP were fair. CONCLUSIONS: Elevated pre-transplant LVEDP increases the risk of severe PGD after lung transplant, as does elevated mPCWP. These measurements appear to be complementary as markers of prospective PGD risk. J Heart Lung Transplant 000;000:1−9 Ó
primary graft dysfunction; lung transplantation; heart failure; diastolic dysfunction; heart failure with preserved ejection fraction; left ventricular end diastolic pressure Primary graft dysfunction (PGD) is the most important contributor to early morbidity and mortality in lung transplant recipients and reflects a combination of allograft ischemia-reperfusion injury, vasogenic pulmonary edema, and inflammatory changes mediated by the innate immune system. 1−3 Patients who develop PGD are at increased risk of poor lung function and death. 4−6 There are limited therapeutic options available to patients who develop PGD after lung transplantation and, as such, the main focus has been on the identification of risk factors for PGD and prevention strategies.
and is the main cause of pulmonary hypertension worldwide. 9 Lung transplant candidates are rigorously screened for cardiac dysfunction, typically focusing on abnormal LV systolic function, which is considered a contraindication to lung transplant alone or may warrant consideration of heart-lung transplant. Increased LV pressure in the absence of systolic dysfunction, however, is not a contraindication to transplantation. 10 Porteous et al showed that an increased E/e 0 ratio-a non-invasive marker of diastolic dysfunction obtained by transthoracic echocardiography-increases the risk of PGD. This, together with a subsequent study in pulmonary hypertension patients, suggests that elevated LV pressure may be contributing to PGD, potentially by increasing interstitial and alveolar fluid passage through an already-injured endothelium. 11 Several invasive and non-invasive metrics exist to measure LV pressure, including direct measurement of LV enddiastolic pressure (LVEDP) and indirect measurement of left atrial pressure through mean pulmonary capillary wedge pressure (mPCWP). Elevated LVEDP has previously been shown to be an independent predictor of mortality in cardiac surgery patients. 12 An LVEDP >15 mm Hg is considered abnormal elevation of LV diastolic pressure. 13 At our center, we routinely perform left (LHC) and right heart catheterization (RHC) with coronary angiography in candidates >50 years of age as well those >40 years old who are believed to have high coronary risk, and this includes measurement of LVEDP and mPCWP. We sought to assess the relationship between elevation of LVEDP and the risk of development of severe PGD at 48 or 72 hours after lung transplant, as well as the relationship between mPCWP and the risk of Grade 3 PGD.
Methods Population
We studied adult patients who underwent double/bilateral lung transplant in the University of Alberta program, between January 1, 2004 and December 31, 2016, with available pre-transplant LVEDP measurements. We excluded all single lung and heartlung transplant recipients, as well as patients lacking LVEDP measurements or sufficient data to grade PGD post-transplant. This study was approved by the health research ethics board of the University of Alberta (Pro00070542).
Cardiac measurements
We used LHC with coronary angiography as well as RHC to evaluate all patients ≥50 years of age and those ≥40 years of age with coronary risk factors. LVEDP was measured in millimeters of mercury (mm Hg) as the pressure immediately preceding isometric ventricular contraction at end expiration. All heart catheterization measurements were performed at the University of Alberta Hospital by our interventional cardiology service. Echocardiography was done via standard of care either at our center or in the community. Standardized echocardiograms performed at a single site are not feasible in our program due to work-up volume and our large referral area. As such, formal measurement and reporting of echocardiographic parameters was up to the reporting site's discretion. No routine interventions were made in patients identified as having increased LVEDP, mPCWP, or E/e 0 ratio.
PGD grading
PGD was graded using the International Society for Heart and Lung Transplantation definition at 4 time-points: 0, 24, 48, and 72 hours post-transplant. 14, 15 Designation of pulmonary edema on chest X-ray was done according to the interpreting radiologist on the original study. We used the binary classification of PGD grade at 48 or 72 hours as the primary end-point, based on previous studies. 16 
Statistics
Continuous variables were summarized using mean or median data and compared using t-tests or Wilcoxon's rank-sum testing, depending on normality. Categorical variables were compared using Fisher's exact test for binary categories and Pearson's chisquare for 3 or more categories. Our primary model assessed the association between our binary covariate of interest, LVEDP >15 mm Hg or ≤15 mm Hg and Grade 3 PGD at 48 or 72 hours post-transplant, using uni-and multivariable logistic regression. We adjusted for body mass index (BMI), mean pulmonary arterial pressure (mPAP), pulmonary diagnosis, donor smoking, and donor age in a multivariable logistic model, based on these parameters' known associations with PGD and their biologic plausibility (rather than variable screening). mPAP was tested for collinearity with LVEDP. Our secondary model assessed the relationship between mPCWP >15 mm Hg and Grade 3 PGD, using analogous uni-and multivariable logistic models. We assessed the level of agreement among LVEDP >15 mm Hg, mPCWP >15 mm Hg, and E/e 0 ratio >8 using k coefficients, and among LVEDP, mPCWP, and E/e 0 ratio as continuous measurements using correlation coefficients. We determined model performance and optimal cut-off threshold for both LVEDP and mPCWP using the area under the curve (AUC) of receiver operating characteristic (ROC) curves. All analyses were performed using JMP version 12 software (SAS Institute, Inc., Cary, NC).
Results
Patient and donor characteristics are shown in Table 1 . A total of 330 patients met the inclusion criteria (Figure 1 ), 64 (19%) of whom developed Grade 3 PGD at 48 or 72 hours. There was no change in the risk of Grade 3 PGD over time (year of transplant p = 0.6932). Donor characteristics associated with the development of Grade 3 PGD were longer ischemic time, older donor age, and heavy donor smoking history. Recipient characteristics, including higher BMI and interstitial lung disease or pulmonary arterial hypertension as indication for transplant, were associated with higher rates of Grade 3 PGD, whereas patients with obstructive lung disease had lower rates. Patients who developed Grade 3 PGD had post-transplant courses with a longer duration of mechanical ventilation and intensive care unit (ICU) and hospital length of stay. Patient characteristics stratified by LVEDP >15 mm Hg are provided in the Supplementary Material available online at www.jhltonline.org/.
Cardiac measurements
Complete cardiac measurements are depicted in Table 2 . Mean LVEDP in patients who developed Grade 3 PGD was higher than in those who did not (16 § 7 mm Hg vs 12 § 5 mm Hg, p < 0.0001; Figure 2 ). Mean PCWP was higher in the Grade 3 PGD group (16 § 8 vs 11 § 7, p < 0.0001; n = 302 patients). Mean mPAP was also higher in the Grade 3 PGD group (32 § 13 vs 26 § 11 mm Hg, p = 0.0006), but the groups did not differ with respect to transpulmonary gradient (TPG = mPAP − mPCWP) or by pulmonary vascular resistance (PVR = mPAP − mPCWP / cardiac output), (24) 17 (27) 61 (23) (8) 8 (13) 17 (6) 
Agreement between metrics of LV filling pressure
We tested the level of agreement among LVEDP, mPCWP, and E/e 0 ratio, both as binary classifiers with k coefficients as well as continuous measurements with correlation coefficients. As binary classifiers, LVEDP >15 mm Hg and mPCWP >15 mm Hg, agreement was fair (k = 0.39), as was the correlation between LVEDP and mPCWP as continuous measurements (correlation coefficient 0.43, p < 0.0001; Figure 3 ). We did not observe a relationship between LVEDP and E/e 0 ratio and mPCWP and E/e 0 ratio, either as binary classifiers or as continuous measurements, although this was based on a smaller sample of patients with complete E/e 0 data (n = 82) ( Table 4 ).
Comparisons of model performance
T a g g e d P We evaluated model performance using the AUC (Figure 4 ). LVEDP and mPCWP performed similarly in univariable models, with an LVEDP AUC of 0.6849 and an mPCWP AUC of 0.6782 for the prediction of Grade 3 PGD at 48 or 72 hours. LVEDP model estimates of Grade 3 PGD risk are depicted in Figure 5 , ranked by LVEDP decile.
Optimal LVEDP and mPCWP threshold identification
We used the ROC tables to determine the optimal threshold balancing sensitivity and specificity for risk classification. An LVEDP of 17 mm Hg was identified as the optimal cutpoint in the univariable model (sensitivity 50%, specificity 82%), whereas a mPCWP of 13 mm Hg was similarly identified (sensitivity 67%, specificity 65%). These values are similar to the guideline recommendations. 13 
Discussion
Our work has shown an important association between elevated pre-transplant LVEDP and the risk of severe PGD in a large cohort of double lung transplant recipients. In addition, our secondary analyses show that mPCWP was complementary in predicting PGD.
LVEDP and mPCWP as classifiers did not consistently identify the same patients, as reflected by the correlation and k coefficients. Their imperfect relationship is not surprising in light of previous work demonstrating interobserver variability when performing these tests, with wedge pressure in particular subject to measurement error in patients with pulmonary hypertension. 17−19 One advantage of our study is the consistency with which our heart catheterization data were obtained by relatively centralized Figure 1 Study cohort. LVEDP, left ventricular end-diastolic pressure; PGD, primary graft dysfunction. 
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assessment by a small number of observers in a single institution on consistent equipment. However, as expected, mPCWP exhibited a greater degree of right skewness compared with LVEDP measurements (skewness: 1.42 vs 0.32), suggesting a tendency toward wedge pressure overestimation. Nonetheless, the overall greater error margins associated with this test (as demonstrated by the larger standard deviation) would more likely serve to increase the error of the risk estimates and bias toward the null as opposed to producing false positives. These results also corroborate previous findings that elevated LV filling pressures increase the risk of PGD. 8 We were interested in modeling PGD risk using the E/e 0 ratio to attempt to reproduce the findings of Porteous et al; however, the small number of patients with available data (n = 89) resulted in insufficient power to analyze this meaningfully. It is important to note that, given this limitation, our study could not directly compare these as predictors. E/e 0 ratio, however, did not agree with LVEDP or mPCWP in patients with complete data in terms of designation of elevated LV pressure, and we did not observe a difference in E/e 0 ratio in patients with Grade 3 PGD and those without. This is potentially consistent with previous studies that questioned the reliability of E/e 0 ratio as a marker of left heart filling pressures, and even other more invasive measurements like mPCWP are only moderately predictive of LVEDP. 20−22 E/e 0 ratio has certainly been found to be a powerful predictor of cardiac events in the non-transplant population, however, and it should be noted that echocardiographic data in our study were standard-of-care rather than via centralized assessment. 23 This, along with our program's large catchment area (»4 million square kilometers) and efforts to allow people to facilitate pre-transplant testing close to home, resulted in echocardiogram interpretation at many different sites and with different reporters (Table 2) , which likely increased variability in the reported metrics, including E/ e 0 ratio (although not outside ranges previously reported in this population). 8 This is an important consideration when interpreting the relationship between the echocardiographic parameters and PGD in our cohort. As with other diagnostic modalities that require training, interpreter and center experience may play a key role in reliability, reproducibility, and utility.
A broader issue is the infrequency with which echocardiographers reported E/e 0 ratio in our real-world echocardiography data, which amounted to roughly 30% of the time (85 of 285 full reports). It is possible that even the decision to report E/e 0 ratio is related to the presence of diastolic dysfunction, with an interpreter potentially being more likely to report the parameter if he or she believes it is abnormal. This type of measurement bias is difficult or even impossible to account for in non-systematically collected data, and, to complicate matters further, this inconsistent reporting applied to many of the echocardiographic estimates of ventricular pressure, dilation, and function in our study. The extent to which this applies at other centers will vary according to local practice, but echocardiography reports are not standardized despite recommendations to that effect. 24, 25 Our study, considered alongside that of Porteous et al, suggests an important contributory mechanism in PGD pathogenesis: hydrostatic pressure in the pulmonary capillary bed. PGD reflects a state of endothelial injury resulting in increased passage of fluid from the capillary bed into the interstitial and alveolar spaces, and it is logical that elevated LV pressure would transmit pressure back to the pulmonary vasculature and increase the rate of this accumulation, overwhelming removal mechanisms just as it does in congestive heart failure. 26 Much of the PGD literature has focused on ruling out LV dysfunction as a potential contributor to edema when setting out PGD definitions. Lung transplant candidates, however, are typically highly selected and patients with significant LV dysfunction are likely to be turned down or offered heart-lung transplant. 10 However, LVEDP as a contributory mechanism to PGD would suggest that either: (a) cardiac factors are in fact an important aspect of the disease pathogenesis; or (b) those cases in which LVEDP plays an important causative role do not meet the strict definition of PGD but rather cardiogenic pulmonary edema through heart failure with preserved ejection fraction (HFpEF).
These findings also have important implications for candidate evaluation, listing, and donor allocation. First and foremost, in patients found to have elevated LVEDP, efforts should be directed at attempting to reduce LV pressure, potentially with diuretics and treatment of comorbid or contributory risk factors including systemic hypertension, sleep-disordered breathing, or coronary artery disease. 13 Whether these efforts to reduce cardiac filling pressures will translate to a reduction in PGD risk will require prospective validation, but given this is recommended therapy independent of transplant candidacy, it is worth pursuing. Second, given our study confirms previous findings, we would advocate that LVEDP can now be used either continuously or as a threshold-based risk factor for PGD during candidate evaluation and donor-recipient allocation. This parameter, when considered with other donor and recipient factors that augment PGD risk, can help facilitate risk approximation at an individual patient level. This could potentially add to already successful efforts at predicting PGD risk. 16, 27 Our study has limitations. The focus on a single center may limit generalizability depending on how LHC and RHC procedures are performed at other centers. The retrospective design also resulted in incomplete data, particularly with respect to echocardiography results, limiting our ability to draw meaningful comparisons with parameters such as E/e 0 ratio. Local surgical preference over the study time-frame resulted in a high rate of cardiopulmonary bypass utilization, and, although this is changing at our center, it could affect PGD rates and augment the relationship between LVEDP and PGD. 2 Elevated pre-transplant LVEDP and mPCWP are associated with increased risk of severe PGD. Future studies 
Figure 3
Correlation between mPCWP and LVEDP in 302 double lung transplant recipients.
are warranted, particularly those focused on whether systematic intervention to reduce elevated LVEDP can reduce PGD risk. 
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Figure 4
Receiver operating curve for LVEDP (left) and mPCWP (right) and the probability of Grade 3 PGD at 47 or 72 hours. LVEDP optimal threshold 17 mm Hg (sensitivity 0.500, specificity 0.8158); mPCWP optimal threshold 12 mm Hg (sensitivity 0.6667, specificity 0.6452).
Figure 5
Predicted grade 3 PGD risk by LVEDP decile.
